Recombinant Human FGFR3 Protein , His

Fibroblast growth factor receptor 3 (FGFR3) is a member of the fibroblast growth factor receptor family that plays a crucial role in bone development and maintenance. Mutations in the FGFR3 gene have been linked to several skeletal disorders, including achondroplasia, the most common form of skeletal dysplasia characterized by disproportionate short stature. The receptor functions as a tyrosine kinase, and its signaling pathways are involved in regulating cell proliferation, differentiation, and survival. Due to its significant role in growth plate regulation and the pathogenesis of various diseases, FGFR3 has emerged as an attractive target for therapeutic intervention. Research on recombinant FGFR3 proteins has enabled the exploration of its structural and functional properties, allowing for a better understanding of its signaling mechanisms in normal physiology and disease states. The use of recombinant technology facilitates the production of FGFR3 in a controlled environment, enabling detailed studies on its interaction with ligands and other cellular components. This research is critical for developing potential treatments that can modulate FGFR3 activity in conditions caused by its dysregulation. Additionally, studying FGFR3 interactions can contribute to the design of inhibitors that may alleviate symptoms of skeletal dysplasias, providing a pathway for innovative therapeutic strategies that can improve patient outcomes.